Why it matters: The pharmaceutical industry’s top trade group dramatically increased its lobbying spend by 70% over last quarter, signaling high stakes in current legislative battles over drug pricing, intellectual property, and federal healthcare funding.
By the numbers:
- $12.88 million spent in Q1 2025
- 70.37% increase from Q4 2024 ($7.56M)
- Nearly double PhRMA’s typical quarterly spend of $6.66M
The big picture: PhRMA is deploying an experienced lobbying team to influence a wave of legislation that could reshape pharmaceutical intellectual property rights, drug pricing, and market competition.
Driving the agenda: Several key patent reform bills have cleared the Senate Judiciary Committee and now sit on the Senate Calendar, including:
- S. 1040: Drug Competition Enhancement Act, targeting "product hopping"
- S. 1041: Affordable Prescriptions for Patients Act, affecting biological product patents
- S. 1095: Stop STALLING Act, empowering the FTC against "sham citizen petitions"
- S. 1096: Preserve Access to Affordable Generics and Biosimilars Act, addressing "pay-for-delay" agreements
Between the lines: The patent-focused legislation has attracted diverse lobbying from groups often at odds with PhRMA, including AARP Inc., Teva Pharmaceuticals USA Inc., and the Association for Accessible Medicines.
The IRA effect: Implementation of the Inflation Reduction Act of 2022 remains a central focus for PhRMA, particularly provisions on Medicare drug price negotiation and redesign of Parts D and B.
Capitol connections: PhRMA’s lobbying team leverages significant committee experience, with members previously serving on key congressional panels:
- David E. Korn, former Chief Health Financial Policy Adviser for the House Energy and Commerce Committee
- Fabian Gabriel Lucero, former Clerk/Counsel for the House Ways and Means Committee
- Lauren Ashley Jee, former Counsel for the Senate Judiciary Committee
- Bridgett Elaine Taylor, former staff member for both House Energy and Commerce and House Judiciary committees
The bigger field: PhRMA’s lobbying occurs alongside significant activity from patient advocacy groups, physician organizations, and competing industry players. On rare disease legislation like the ORPHAN Cures Act (H.R. 946) and the Give Kids a Chance Act (S. 932/H.R. 1262), PhRMA’s interests sometimes align with patient foundations and biotech companies.
The bottom line: This record-level spending underscores the pharmaceutical industry’s perception that 2025 could bring transformative changes to drug development incentives, patent protections, and pricing models. With multiple bills advancing through Congress and IRA implementation ongoing, the stakes for PhRMA’s members have rarely been higher.